{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:12:18Z","timestamp":1791727938117,"version":"4.3.4"},"reference-count":78,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive age. This condition is characterized by hyperandrogenism and either oligo- or anovulation. PCOS patients often present comorbidities such as obesity, insulin resistance, impaired glucose metabolism, dyslipidemia, hypertension, metabolic syndrome, and an increased risk of diabetes. Given the profound implications of metabolic impairment in PCOS, the accurate diagnosis and management of these facets are imperative. The first-line approach to treatment involves lifestyle modifications, including dietary adjustments and exercise aimed at achieving weight loss, a strategy consistently emphasized across the literature. Supplementation with probiotics, vitamin D, and L-carnitine have also provided additional benefits to patients. In select cases, pharmacological interventions are needed for optimal therapeutic results. The most common medications used in PCOS include metformin, thiazolidinediones, inositols, and two classes of antidiabetic agents: dipeptidyl peptidase-IV (DPP-IV) inhibitors, and sodium\u2013glucose cotransporter-2 (SGLT-2) inhibitors. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new addition to the therapeutic arsenal for the metabolic management of PCOS. GLP-1 receptor agonists cause insulin release in a glucose-dependent manner, yielding clinical benefits such as heightened satiety, reduced appetite, and appetite regulation. GLP-1RAs have demonstrated efficacy in reducing glycated hemoglobin levels and promoting weight loss while ameliorating hyperlipidemia. Prior to initiating GLP-1RA therapy, patients should undergo screening for contraindications, including history of pancreatitis, diabetic retinopathy, or thyroid cancer. The effects of treatment should be monitored using laboratory testing and body weight measurements. Effective communication between clinician and patient should be maintained with regular check-in for a period of 6 to 12 months.<\/jats:p>","DOI":"10.3390\/jcm12185915","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T03:54:06Z","timestamp":1694490846000},"page":"5915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies"],"prefix":"10.3390","volume":"12","author":[{"given":"Aleksandra","family":"Szczesnowicz","sequence":"first","affiliation":[{"name":"Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Szeliga","sequence":"additional","affiliation":[{"name":"Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Niwczyk","sequence":"additional","affiliation":[{"name":"Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Bala","sequence":"additional","affiliation":[{"name":"UCD School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blazej","family":"Meczekalski","sequence":"additional","affiliation":[{"name":"Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment","volume":"14","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rotterdam ESHRE\/ASRM\u2013Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril., 81, 19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"ref_3","first-page":"887","article-title":"Cardiometabolic biomarkers in women with polycystic ovary syndrome","volume":"17","author":"Louvers","year":"2022","journal-title":"Fertil. Steril."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/cen.13477","article-title":"The association between metabolic syndrome and polycystic ovary syndrome: A systematic review and meta-analysis","volume":"88","author":"Otaghi","year":"2018","journal-title":"Clin. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/humupd\/dms030","article-title":"Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta analysis","volume":"18","author":"Lim","year":"2012","journal-title":"Hum. Reprod. Update"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications","volume":"33","author":"Dunaif","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cbin.11129","article-title":"Regulation of insulin resistance by targeting the insulin-like growth factor 1 receptor with microRNA-122-5p in hepatic cells","volume":"43","author":"Dong","year":"2019","journal-title":"Cell Biol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13048-020-00670-3","article-title":"Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: A review","volume":"13","author":"He","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chen, W., and Pang, Y. (2021). Metabolic Syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites, 11.","DOI":"10.3390\/metabo11120869"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/09513590400027265","article-title":"Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome","volume":"20","author":"Yilmaz","year":"2005","journal-title":"Gynecol. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/humupd\/dmr046","article-title":"Carotid artery intima-media thickness in polycystic ovary syndrome: A systematic review and meta-analysis","volume":"18","author":"Meyer","year":"2012","journal-title":"Hum. Reprod. Update"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12958-019-0509-4","article-title":"Polycystic ovary syndrome and mitochondrial dysfunction","volume":"17","author":"Zhang","year":"2019","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.coemr.2021.01.002","article-title":"Role of obstructive sleep apnea in metabolic risk in PCOS","volume":"17","author":"Sam","year":"2021","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/osp4.124","article-title":"The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity","volume":"3","author":"Coveleskie","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s13300-021-01113-y","article-title":"Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)","volume":"12","author":"Kalra","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_21","unstructured":"Eli Lilly and Company (2023, July 13). Trulicity (Dulaglutide) Injection for Subcutaneous Use; Prescribing Information. Available online: https:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Christensen","year":"2012","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial","volume":"389","author":"Astrup","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.peptides.2017.12.009","article-title":"Newer GLP-1 receptor agonists and obesity-diabetes","volume":"100","author":"Brown","year":"2018","journal-title":"Peptides"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"Birkenfeld","year":"2018","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad. Med."},{"key":"ref_34","first-page":"53","article-title":"Metabolic health during a randomized controlled lifestyle intervention in women with PCOS","volume":"186","author":"Jiskoot","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-981-15-1792-1_8","article-title":"Exercise and Polycystic Ovary Syndrome","volume":"1228","author":"Woodward","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"808898","DOI":"10.3389\/fendo.2022.808898","article-title":"Life Modifications and PCOS: Old Story but New Tales","volume":"13","author":"Gu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Giampaolino, P., Foreste, V., Di Filippo, C., Gallo, A., Mercorio, A., Serafino, P., Improda, F.P., Verrazzo, P., Zara, G., and Buonfantino, C. (2021). Microbiome and PCOS: State-of-Art and Future Aspects. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042048"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Szczuko, M., Kikut, J., Szczuko, U., Szyd\u0142owska, I., Nawrocka-Rutkowska, J., Zi\u0119tek, M., Verbanac, D., and Saso, L. (2021). Nutrition Strategy and Life Style in Polycystic Ovary Syndrome-Narrative Review. Nutrients, 13.","DOI":"10.3390\/nu13072452"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101894","DOI":"10.1016\/j.jogoh.2020.101894","article-title":"Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): How to achieve weight loss in overweight and obese women with PCOS?","volume":"50","author":"Douma","year":"2021","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12967-017-1175-y","article-title":"Influence of diet on the gut microbiome and implications for human health","volume":"15","author":"Singh","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13048-018-0457-1","article-title":"The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome","volume":"11","author":"Jamilian","year":"2018","journal-title":"J. Ovarian Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1017\/S0954422409389301","article-title":"Vitamin D: Emerging new roles in insulin sensitivity","volume":"22","author":"Teegarden","year":"2009","journal-title":"Nutr. Res. Rev."},{"key":"ref_43","first-page":"757","article-title":"Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: A pilot study","volume":"34","author":"Wehr","year":"2011","journal-title":"J. Endocrinol. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1007\/s12325-021-01789-5","article-title":"Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial","volume":"38","author":"Tauqir","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00394-021-02659-0","article-title":"The effect of L-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight\/obese women with polycystic ovary syndrome: A randomized clinical trial","volume":"61","author":"Sangouni","year":"2022","journal-title":"Eur. J. Nutr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-09-0733","article-title":"Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome","volume":"162","author":"Christakou","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12978-021-01207-7","article-title":"Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: A network meta-analysis","volume":"18","author":"Zhao","year":"2021","journal-title":"Reprod. Health"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diabres.2017.06.011","article-title":"Insulin and the polycystic ovary syndrome","volume":"130","author":"Macut","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis","volume":"23","author":"Panunzi","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tjog.2021.11.009","article-title":"Polycystic ovarian syndrome-current pharmacotherapy and clinical implications","volume":"61","author":"Rashid","year":"2022","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","article-title":"DPP-4 inhibitors and their potential role in the management of type 2 diabetes","volume":"60","author":"Barnett","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/dom.14495","article-title":"Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial","volume":"23","author":"Tan","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/dom.12050","article-title":"Extra-pancreatic effects of incretin-based therapies: Potential benefit for cardiovascular-risk management in type 2 diabetes","volume":"15","author":"Diamant","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: A pilot randomized study","volume":"8","author":"Jensterle","year":"2015","journal-title":"J. Ovarian Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial","volume":"20","author":"Nylander","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kahal, H., Aburima, A., Ungvari, T., Rigby, A.S., Coady, A.M., Vince, R.V., Ajjan, R.A., Kilpatrick, E.S., Naseem, K.M., and Atkin, S.L. (2015). The Effects of Treatment with Liraglutide on Atherothrombotic Risk in Obese Young Women with Polycystic Ovary Syndrome and Controls. BMC Endocr. Disord., 15.","DOI":"10.1186\/s12902-015-0005-6"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: A randomized placebo-controlled-phase 3 study","volume":"118","author":"Chappell","year":"2022","journal-title":"Fertil. Steril."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cen.12369","article-title":"Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease","volume":"81","author":"Kahal","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/09513590.2018.1505848","article-title":"The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls","volume":"35","author":"Kahal","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6820377","DOI":"10.1155\/2022\/6820377","article-title":"Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations","volume":"2022","author":"Xu","year":"2022","journal-title":"Cardiovasc. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: A pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17512433.2021.1933433","article-title":"Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome","volume":"14","author":"Siamashvili","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2042018821989238","DOI":"10.1177\/2042018821989238","article-title":"The potential role of incretin-based therapies for polycystic ovary syndrome: A narrative review of the current evidence","volume":"12","author":"Abdalla","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Jensterle, M., Herman, R., and Jane\u017e, A. (2022). Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081989"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/jwh.2020.8683","article-title":"Obstetrician-Gynecologists\u2019 Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists","volume":"30","author":"Gill","year":"2021","journal-title":"J. Womens Health"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: A clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00404-015-3976-7","article-title":"A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries","volume":"293","author":"Niafar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: A randomized clinical trial","volume":"35","author":"Nylander","year":"2017","journal-title":"Reprod. Biomed. Online"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_76","unstructured":"B\u0105k-Sosnowska, M., Bia\u0142kowska, M., Bogda\u0144ski, P., Chomiuk, T., Ga\u0142\u0105zka-Sobotka, M., Holecki, M., Jarosi\u0144ska, A., Jezierska, M., Kami\u0144ski, P., and K\u0142oda, K. (2022). Zalecenia kliniczne dotycz\u0105ce post\u0119powania u chorych na oty\u0142o\u015b\u0107 2022\u2013stanowisko Polskiego Towarzystwa Leczenia Oty\u0142o\u015bci. Med. Prakt. Wyd. Specj., 1\u201387."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"Filippatos","year":"2013","journal-title":"World J. Diabetes"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"D1","DOI":"10.1530\/EJE-18-0237","article-title":"Diagnosis and follow-up of type 2 diabetes in women with PCOS: A role for OGTT?","volume":"179","author":"Andersen","year":"2018","journal-title":"Eur. J. Endocrinol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:49:16Z","timestamp":1760129356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":78,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12185915"],"URL":"https:\/\/doi.org\/10.3390\/jcm12185915","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]}}}